OBJECTIVES: To describe the economic burden of anti-TNFs biosimilar consumption in France thanks to an analysis of claims healthcare data available in open access.

METHODS: Data from Open Medic 2014 to 2021 datasets, which include data on annual drug expenditures as well as the number of boxes dispensed, according to descriptive elements on beneficiaries (age group, gender, region of residence) and information on the prescriber's specialty among drugs delivered in community pharmacies (outside hospital) were exploited and reprocessed.

RESULTS: A total of 1,442,654 boxes of anti-TNF were sold in France in 2021 for 148,771 patients. This represented 840 million of euros reimbursed by the French social insurance in 2021. The penetration rate, in terms of number of boxes sold, has increased from 3.5% of biosimilars in 2018, 12.8% in 2019, 22.1% in 2020 and 27.5% in 2021. Costs saving generated by the current use of anti-TNF biosimilars was up to 49 million of euros in 2021 as expenses could have been up to 889 million of euros without biosimilars. Disparities have been observed across regions regarding the repartition of anti-TNF expenses between biosimilars and original drug. In particular, the expenses related to biosimilars represent 25.6% in the Paris region (Ile de France), whereas it represents 19,8% in the south/west of France (Occitanie). The poster will be updated with data from 2022.

CONCLUSIONS: This study showed that an increased use of biosimilars can strongly decrease French insurance expenses related to the consumption of anti-TNF. Even though anti-TNF biosimilars are more and more used over the years, they still represent less than 30%of the total amount of anti-TNF boxes sold in France in 2021. This work also highlights the strong interest that can have the reuse of open data provided by the French national social insurance on drug consumption and expenditures in France.